Pure Global
NCT05074849

Benefits of Insoles With Real-Time Alert and Foot Self-Care Education

Benefits of Insoles With Real-Time Alert and Foot Self-Care Education in Improving Adherence for Prescribed Footwear in Patients With Diabetes Mellitus
Texas Woman's University·ClinicalTrials.gov·behavioralNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Diabetes Complications
Drug/Device/Intervention
A 90-minute self-care education + bi-weekly 30-minute one-on-one follow-up phone discussion
Study type
Interventional
Intervention type
behavioral
Sponsor & location
Primary sponsor
Texas Woman's University
Location
Houston,Houston, United States of America
Timeline & enrollment
Phase
N/A
Start date
Jul 20, 2022
End date
Dec 30, 2024
Enrollment
72 participants
Primary outcome

A Change in Adherence to prescribed footwear is being assessed

Summary

Novel approaches to promote adherence to diabetic footwear and prevent high incidence of
 diabetes foot ulcers are urgently needed. Investigators propose to translate an innovative
 and practical technology to supplement clinical and risk evaluation for patients with
 diabetes through wearable insoles and smart watch, along with foot self-care education, to
 improve adherence to prescribed footwear and reduce incidence of foot ulcers in those with
 diabetes and at risk for foot ulcers.

ICD-10 classifications
Unspecified diabetes mellitus without complicationsOther specified diabetes mellitus with other specified complicationsOther specified diabetes mellitus without complicationsUnspecified diabetes mellitus with other specified complicationsOther specified diabetes mellitus with unspecified complications
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05074849
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05074849 through Pure Global AI's free database. This phase not specified trial is sponsored by Texas Woman's University and is currently Not yet recruiting. The study focuses on Diabetes Complications. Target enrollment is 72 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.